SEOM clinical guidelines for endometrial cancer (2017)

A. Santaballa ^[1] ; X. Matías-Guiu ^[2] ; A. Redondo ^[3] ; N. Carballo ^[9] ; M. Gil ^[4] ; C. Gómez ^[5] ; M. Gorostidi ^[6] ; M. Gutierrez ^[7] ; A. Gónzalez-Martín ^[8]
1. [1] Hospital Universitario La Fe
  
  Hospital Universitario La Fe
  
  Valencia, España
2. [2] Hospital Universitari de Bellvitge
  
  Hospital Universitari de Bellvitge
  
  l'Hospitalet de Llobregat, España
3. [3] Hospital Universitario La Paz
  
  Hospital Universitario La Paz
  
  Madrid, España
4. [4] Hospital Duran i Reynals
  
  Hospital Duran i Reynals
  
  Barcelona, España
5. [5] Hospital Infanta Sofia
  
  Hospital Infanta Sofia
  
  Madrid, España
6. [6] Hospital Universitario de Donostia
  
  Hospital Universitario de Donostia
  
  San Sebastián, España
7. [7] Hospital Universitario Araba
  
  Hospital Universitario Araba
  
  Vitoria, España
8. [8] Clínica Universitaria de Navarra
  
  Clínica Universitaria de Navarra
  
  Pamplona, España
9. [9] MD Anderson Cancer Center, Madrid, España
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 1 (January 2018), 2018, págs. 29-37
Idioma: inglés
Texto completo no disponible (Saber más ...)

Resumen
- Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.